NCT07387263Recruiting
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon/GI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer centres are 'mainstreaming' genetic testing - whereby genetic testing is initiated and mediated by oncologists without traditional pre-test genetic counseling (GC) often using some form of paper-based patient pamphlets or videos. There is no standard, evidence-based approach to mainstreaming, leading to significant practice variation, a lack of coordinated care and ultimately, negative psychological impacts on patients. Digital solutions can address these gaps by providing a standardized, coordinated and patient-centered approach to deliver cancer genetic education. However, digital solutions for providing cancer genetics services are uncommon and clinical-effectiveness and service delivery outcomes have not been well-assessed. This study will test a digital mainstreaming platform called the Genetics Adviser for Mainstream care to assess its effectiveness in improving psychological outcomes and patient-centred care for mainstream cancer patients compared to standard of care.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- First submitted
- 17 Dec 2025
- Start date
- 30 Apr 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Unity Health Toronto
- NCT number
- NCT07387263
What you commit to
- Study type: Interventional
- Planned participants: 180
- From 30 Apr 2026 to the primary completion date, 31 Dec 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving genetic testing information via a referral to a genetics clinic
Age
- Under 18 years of age
Other
- Do not speak or read English
- Determined to have diminished, marginal and or fluctuating decisional capacity
- Lack access to internet or an electronic device
Who the study is looking for
- Receiving mainstream cancer germline testing related to primary cancer condition (ie. ovarian, pancreas, breast, prostate, or GI cancers) initiated by an oncologist.
- 18 years old or older.
- Speak and read English
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sunnybrook Hospital Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
| Mount Sinai Hospital Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.